Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population

被引：0
|
作者：
Leif Bjermer
Job F. M. van Boven
Madlaina Costa-Scharplatz
Dorothy L. Keininger
Florian S. Gutzwiller
Karin Lisspers
Ronan Mahon
Petter Olsson
Nicolas Roche
机构：
[1] Skane University Hospital,Department of Respiratory medicine & Allergology
[2] Lund University,Department of General Practice
[3] Groningen Research Institute for Asthma and COPD (GRIAC),Unit of Pharmacoepidemiology & Pharmacoeconomics, Department of Pharmacy
[4] University Medical Center Groningen,Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine
[5] University of Groningen,Respiratory and Intensive Care Medicine
[6] University of Groningen,undefined
[7] Novartis Sverige AB,undefined
[8] Novartis Pharma AG,undefined
[9] Uppsala University,undefined
[10] Novartis Ireland Limited,undefined
[11] Cochin Hospital (AP-HP) and University Paris Descartes,undefined
来源：
Respiratory Research | / 18卷
关键词：
Chronic obstructive pulmonary disease; Indacaterol/glycopyrronium; Cost-effective; Exacerbation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 42 条
  • [21] EFFECT OF INDACATEROL/GLYCOPYRRONIUM ON THE TIME TO FIRST MODERATE OR SEVERE COPD EXACERBATION VERSUS SALMETEROL/FLUTICASONE BY BASELINE BLOOD EOSINOPHIL LEVELS: FINDINGS FROM THE FLAME STUDY
    Wedzicha, J. A.
    Vogelmeier, C.
    Larbig, M.
    Patalano, F.
    Thach, C.
    Fogel, R.
    Banerji, D.
    RESPIROLOGY, 2016, 21 : 117 - 117
  • [22] Indacaterol/Glycopyrronium Reduces Moderate or Severe Exacerbations Compared With Salmeterol/Fluticasone, Irrespective of Number of Exacerbations in Previous Year: Indirect Comparison From FLAME and LANTERN Studies
    Yadao, Anthony
    Fogel, Robert
    Ayers, Tim
    Thach, Chau
    Patalano, Francesco
    Banerji, Donald
    CHEST, 2016, 150 (04) : 1317A - 1317A
  • [23] Once-daily indacaterol/glycopyrronium (IND/GLY) reduces all exacerbations compared with twice-daily salmeterol/fluticasone (SFC) in COPD patients with ≥ 1 exacerbation in the previous year: The FLAME study
    Wedzicha, Jadwiga
    Vogelmeier, Claus F.
    Ayers, Tim
    FowlerTaylor, Angel
    Thach, Chau
    Olsson, Petter
    Fogel, Robert
    Patalano, Francesco
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [24] INDACATEROL/GLYCOPYRRONIUM (IND/GLY) IS SUPERIOR TO SALMETEROL/FLUTICASONE (SFC) IN ASIAN PATIENTS WITH MODERATE-TO-VERY SEVERE COPD AT A HIGH RISK OF EXACERBATIONS: FLAME STUDY RESULTS
    Wedzicha, J. A.
    Zhong, N.
    Ichinose, M.
    Larbig, M.
    Humphries, M.
    Fogel, R.
    Thach, C.
    Patalano, F.
    Banerji, D.
    RESPIROLOGY, 2016, 21 : 180 - 180
  • [25] Indacaterol/glycopyrronium (IND/GLY) is superior to salmeterol/fluticasone (SFC) in improving the health status of patients with moderate-to-very severe COPD: Results from the FLAME study
    Chapman, Kenneth R.
    Roche, Nicolas
    Ayers, Tim
    FowlerTaylor, Angel
    Thach, Chau
    Ahlers, Norbert
    Fogel, Robert
    Patalano, Francesco
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [26] Indacaterol/glycopyrronium (IND/GLY) is more effective than salmeterol/fluticasone (SFC) in reducing exacerbations, regardless of outcome measurement utilised: Results from the FLAME study
    Keininger, Dorothy
    Wedzicha, Jadwiga A.
    Vestbo, Jorgen
    Ayers, Tim
    FowlerTaylor, Angel
    Thach, Chau
    Larbig, Michael
    Askin, Elaine
    Fogel, Robert
    Patalano, Francesco
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [27] ONCE-DAILY INDACATEROL/GLYCOPYRRONIUM (IND/GLY) IS MORE EFFECTIVE THAN TWICE-DAILY SALMETEROL/FLUTICASONE (SFC) IN REDUCING EXACERBATIONS IN COPD PATIENTS AT A HIGH RISK OF EXACERBATIONS: THE FLAME STUDY
    Wedzicha, J. A.
    Chapman, K. R.
    Larbig, M.
    Patalano, F.
    Thach, C.
    Fogel, R.
    Banerji, D.
    RESPIROLOGY, 2016, 21 : 116 - 116
  • [28] Effect of indacaterol/glycopyrronium (IND/GLY) vs salmeterol/fluticasone (SFC) on moderate or severe COPD exacerbations and lung function based on baseline blood eosinophil counts: Results from the FLAME study
    Chapman, Kenneth R.
    Vogelmeier, Claus F.
    FowlerTaylor, Angel
    Ayers, Tim
    Thach, Chau
    Shrinivasan, Anupama
    Fogel, Robert
    Patalano, Francesco
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [29] EFFECT OF INDACATEROL/GLYCOPYRRONIUM (IND/GLY) VS SALMETEROL/FLUTICASONE (SFC) ON MODERATE OR SEVERE COPD EXACERBATIONS AND LUNG FUNCTION BASED ON BASELINE BLOOD EOSINOPHIL COUNTS: RESULTS FROM THE FLAME STUDY
    Chapman, Kenneth R.
    Vogelmeier, Claus F.
    FowlerTaylor, Angel
    Ayers, Tim
    Thach, Chau
    Shrinivasan, Anupama
    Fogel, Robert
    Patalano, Francesco
    Banerji, Donald
    RESPIROLOGY, 2017, 22 : 85 - 85
  • [30] Effect of indacaterol/glycopyrronium versus salmeterol/fluticasone on hypothalamic pituitary-adrenal axis function in moderate-to-very severe COPD patients: Results from the FLAME study
    Olsson, Petter
    Vogelmeier, Claus
    Chapman, Kenneth
    FowlerTaylor, Angel
    Ayers, Tim
    Thach, Chau
    Fogel, Robert
    Patalano, Francesco
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
12345